Adverum Biotechnologies Inc (NASDAQ: ADVM) shares gained 2.13%, or $0.05 per share, to close Wednesday at $2.40. After opening the day at $2.32, shares of Adverum fluctuated between $2.42 and $2.29. 853,461 shares traded hands a decrease from their 30 day average of 1,626,358. Wednesday’s activity brought Adverum’s market cap to $235,502,078.
Adverum is headquartered in Redwood City, California..
About Adverum Biotechnologies Inc
Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema.